It's hard enough to pick winners in biotech, but when companies try to explain away bad trial data with "don't look at that, look at *this*" post hoc analysis, all manner of alarms and sirens should go off in investors' heads. And yet, for every rule there is an exception, and I think Amicus Therapeutics (FOLD) may just be that rare exception. While I realize that hope and belief are more suited to theology than biotechnology, I do believe that Amicus's lead drug is effective and safe, and I hope that a 12-month follow-up of its pivotal study will be able to demonstrate that sufficiently for the FDA to grant approval.
A Promising Drug Comes A Cropper
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: